Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye implant could give glaucoma patients a clearer future

NCT ID NCT07220876

Disease control Sponsor: Avisi Technologies Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This trial tests a tiny device called the VisiPlate shunt to help drain fluid and lower eye pressure in people with open-angle glaucoma that hasn't responded to other treatments. About 165 adults will receive the implant and be followed to see if their eye pressure drops by at least 20%. The goal is to control the disease and prevent further vision loss, not to cure it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 165 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Open angle, pseudoexfoliative or pigmentary glaucoma * IOP at preoperative visit of ≥ 20mmHg and ≤ 40mmHg * Visual field mean deviation score of -3dB or worse * Area of healthy, free and mobile conjunctiva in the target quadrant * Shaffer angle grade ≥ 2 in the target quadrant Exclusion Criteria: * Angle closure glaucoma * Congenital, neovascular or other secondary glaucomas * Previous intraocular surgery, with the exception of uncomplicated cataract surgery * Previous glaucoma shunt/valve in the target quadrant * Clinically significant inflammation or infection in the study eye within 30 days prior to the operative visit * History of corneal surgery, corneal opacities or corneal disease * Retinal or optic nerve disorders, either degenerative or evolutive, that are not associated with the existing glaucoma condition

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Open-angle glaucoma (OAG) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

exfoliation syndrome glaucoma open-angle glaucoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Open-angle glaucoma (OAG)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Arizona Advanced Eye Research

    RECRUITING

    Glendale, Arizona, 85306, United States

  • Cleveland Clinic- Cole Eye Institute

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44195, United States

  • Glaucoma Associates of Texas

    RECRUITING

    Dallas, Texas, 75231, United States

  • ICON Eye Care

    RECRUITING

    Grand Junction, Colorado, 81501, United States

  • Lynette Venter

    NOT_YET_RECRUITING

    Bloemfontein, 9301, South Africa

  • Mile High Eye Institute

    WITHDRAWN

    Sheridan, Colorado, 80226, United States

  • Pretoria Eye Institute

    NOT_YET_RECRUITING

    Pretoria, 0007, South Africa

  • Sacramento Eye Consultants

    RECRUITING

    Sacramento, California, 95815, United States

  • Scheie Eye Institute

    NOT_YET_RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

  • The Eye Centers of Racine & Kenosha

    RECRUITING

    Kenosha, Wisconsin, 53142, United States

  • University of Texas Southwestern

    NOT_YET_RECRUITING

    Dallas, Texas, 75390, United States

  • Wills Eye Hospital

    NOT_YET_RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.